Emmaus Life Sciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

ACQUISITION (Tables)

ACQUISITION (Tables)

6 Months Ended

Mar. 31, 2018

Schedule of consideration for Arcadian Services

The following table summarizes the allocation of the purchase consideration and the estimated fair value of the assets acquired and the liabilities assumed for the acquisition of Arcadian Services made by the Company:

Assets acquired:
Cash	$	25,900
Accounts receivable		57,100
Other assets		24,000
Intangibles		109,000
Goodwill		1,386,800
Total assets acquired	$	1,602,800

Liabilities assumed
Accounts payable	$	147,700
Accrued other liabilities		108,700
Notes payable		6,800
Total liabilities assumed	$	263,200

Net assets acquired	$	1,339,600

Consideration paid:
Initial investment in Arcadian Services		195,900
Long-term debt		555,000
Accrued interest		96,700
Payment on warrant outstanding		175,000
Forgiveness of loan in relation of acquisition
		317,000
Total consideration	$	1,339,600

Schedule of unaudited Pro Forma Financial Information

The pro forma adjustments are based upon available information and certain assumptions that the Company believes are reasonable.

	For Three Months Ended March 31,						For Six Months Ended March 31,
	2018			2017			2018			2017
Revenues	$	459,900		$	282,300		$	727,200		$	541,500
Net income (loss)	$	(2,659,600	)	$	(1,544,500	)	$	(5,605,300	)	$	(3,333,500	)
Basic and diluted loss per share:	$	(0.61	)	$	(0.65	)	$	(1.29	)	$	(1.49	)

Outstanding at Weighted average shares outstanding		4,362,564			2,372,394			4,347,745			2,236,728